Business Context and Reporting Period
PDS Biotechnology Corp (PDSB) filed a Form 8-K on September 12, 2026, reporting events occurring on September 14, 2026. The filing details the completion of a private placement offering, the redemption of a material promissory note, and significant changes to the Board of Directors.
Key Financial Metrics and Transactions
- Capital Raise: The Company completed the initial closing of a private placement, receiving gross proceeds of approximately $11.3 million.
- Securities Issued: In connection with the raise, the Company issued 16,502,870 shares of common stock, pre-funded warrants for up to 23,498,156 shares, and common warrants for up to 20,005,14 shares.
- Debt Redemption: The Company redeemed in full the "Yorkville Note" (originally $6.0 million principal) by paying an aggregate redemption amount of approximately $4.6 million, covering all outstanding principal and accrued interest.
- Liquidity Impact: The filing indicates a net cash inflow from the capital raise and a reduction in debt obligations, though specific post-transaction cash balances are not provided.
Material Changes Versus Prior Period
- Debt Reduction: The Company eliminated a $6.0 million promissory note obligation that was due in June 2027, paying it off early without incurring early termination penalties.
- Board Composition: The Board size increased from six to eight directors. Dr. Patrick Soon-Shiong and Mr. James Banaag were appointed as new directors.
- Ownership Structure: Nant Capital, LLC and affiliates (controlled by Dr. Soon-Shiong) purchased approximately $10.0 million of securities in the initial closing and hold board designation rights for two seats.
Guidance, Outlook, and Management Commentary
- Strategic Partnerships: NantWorks, controlled by Dr. Soon-Shiong, entered into an option to negotiate an exclusive license for the Company's PDS0101 compound for $25,000.
- Future Obligations: Nant is obligated to purchase additional securities for an aggregate subscription amount of $10.0 million upon the occurrence of a defined "Milestone Event."
- Director Independence: The Board waived the Nasdaq independence requirement for the two new Nant-designated directors. Dr. Ilian Iliev, Ph.D., was re-evaluated and confirmed as an independent director.
- Compensation: The new directors will not receive initial equity grants but are eligible for the standard non-employee director compensation program.
Investor Verification Checklist
- Verify the exact terms and definition of the "Milestone Event" triggering the additional $10.0 million purchase obligation by Nant.
- Confirm the dilution impact of the 16.5 million shares and 43.5 million warrants issued in the private placement.
- Review the specific terms of the option to negotiate the exclusive license for PDS0101 with NantWorks.
- Assess the Company's remaining cash position post-redemption and capital raise to evaluate runway for operations.